Events Archives - Telix Pharmaceuticals Limited | Telix Pharmaceuticals Limited

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy.

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

Telix today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026.

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

Telix today advises that it will host advises that it will host a Capital Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.m. to 12:30 p.m. (AEDT).

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

Telix advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference, both in New York, NY.

Telix to Host R&D Day in New York City

Telix today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.

Telix H1 2026 Results: Investor Webcast Notification

Telix today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026.

Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

Telix today officially opens a multi-million dollar radiopharmaceutical research, manufacturing and treatment facility in Melbourne, expanding and strengthening Australia’s capability in one of the world’s fastest-growing areas of cancer diagnosis and treatment.

First Patients Dosed in Optimal-e Trial for Earlier Stage Prostate Cancer

Telix and St Vincent’s Hospital today announced that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent’s Hospital in Sydney, Australia.

FDA Alignment to Advance ProstACT Global Phase 3 Trial

Telix today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial of its therapeutic candidate TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in metastatic castration resistant prostate cancer.

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

Telix today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these.